122 related articles for article (PubMed ID: 1365428)
1. Structure activity relationship and therapeutic uses of dopaminergic ergots.
Markstein R; Seiler MP; Jaton A; Briner U
Neurochem Int; 1992 Mar; 20 Suppl():211S-214S. PubMed ID: 1365428
[No Abstract] [Full Text] [Related]
2. Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism.
Gomez-Mancilla B; Boucher R; Bédard PJ
Mov Disord; 1992; 7(1):43-7. PubMed ID: 1348351
[TBL] [Abstract][Full Text] [Related]
3. The pharmacology of ergots: past and present.
Lemberger L
Fed Proc; 1978 Jun; 37(8):2176-80. PubMed ID: 26605
[No Abstract] [Full Text] [Related]
4. Structure-activity relationships in the trans-hexahydroindolo[4,3-ab]phenanthridine ("benzergoline") series. 2. Resolution, absolute configuration, and dopaminergic activity of the selective D1 agonist CY 208-243 and its implication for an "extended rotamer-based dopamine receptor model".
Seiler MP; Floersheim P; Markstein R; Widmer A
J Med Chem; 1993 Apr; 36(8):977-84. PubMed ID: 8097540
[TBL] [Abstract][Full Text] [Related]
5. DA agonists -- ergot derivatives: cabergoline: management of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S68-71. PubMed ID: 12211142
[No Abstract] [Full Text] [Related]
6. Enantioselective total synthesis of (+)-lysergic acid, (+)-lysergol, and (+)-isolysergol by palladium-catalyzed domino cyclization of allenes bearing amino and bromoindolyl groups.
Inuki S; Iwata A; Oishi S; Fujii N; Ohno H
J Org Chem; 2011 Apr; 76(7):2072-83. PubMed ID: 21361331
[TBL] [Abstract][Full Text] [Related]
7. Dopaminephilic properties of ergot alkaloids.
Goldstein M; Lew JY; Nakamura S; Battista AF; Lieberman A; Fuxe K
Fed Proc; 1978 Jun; 37(8):2202-6. PubMed ID: 26607
[No Abstract] [Full Text] [Related]
8. On the chromatography of hydrogenated ergot alkaloids of the ergotoxine group.
ADAMANIS F; PAWELCZYK E; PLOTKOWIAKOWA Z
Bull Soc Amis Sci (Med) (Poznan); 1960; C-10():95-104. PubMed ID: 14448225
[No Abstract] [Full Text] [Related]
9. A clinical evaluation of the treatment of hypertension with dihydrogenated ergotoxine alkaloids.
SUTTON GC; BUCKINGHAM W; BROWN RD; SUTTON DC
Am Heart J; 1952 Oct; 44(4):622-8. PubMed ID: 12976346
[No Abstract] [Full Text] [Related]
10. Progress in the medicinal chemistry of dopaminergic agents.
Schaus JM; Kornfeld EC; Titus RD; Nichols CL; Huser DL; Clemens JA; Smalstig EB; Fuller RW
Drug Des Discov; 1993; 9(3-4):323-32. PubMed ID: 8104521
[TBL] [Abstract][Full Text] [Related]
11. The pathophysiology of hyperprolactinemic states and the role of newer ergot compounds in their treatment.
Frantz AG; Kleinberg DL
Fed Proc; 1978 Jun; 37(8):2192-7. PubMed ID: 26606
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological basis for the therapeutic use of ergot alkaloids].
Tran MA; Montastruc JL; Montastruc P
Presse Med; 1983 Feb; 12(8):517-20. PubMed ID: 6131414
[TBL] [Abstract][Full Text] [Related]
13. [Sympathicolytic and adrenolytic actions of some alkaloids of ergotoxine].
MENDEZ L
Arch Inst Cardiol Mex; 1951 Apr; 21(2):196-204. PubMed ID: 14858106
[No Abstract] [Full Text] [Related]
14. [The therapy of hyperprolactinemia].
von Werder K
Dtsch Med Wochenschr; 1992 Dec; 117(51-52):1967-70. PubMed ID: 1362148
[No Abstract] [Full Text] [Related]
15. trans-hexahydroindolo[4,3-ab]phenanthridines ("benzergolines"), the first structural class of potent and selective dopamine D1 receptor agonists lacking a catechol group.
Seiler MP; Hagenbach A; Wüthrich HJ; Markstein R
J Med Chem; 1991 Jan; 34(1):303-7. PubMed ID: 1671417
[TBL] [Abstract][Full Text] [Related]
16. Proposed dopaminergic pharmacophore of lergotrile, pergolide, and related ergot alkaloid derivatives.
Cannon JG; Demopoulos BJ; Long JP; Flynn JR; Sharabi FM
J Med Chem; 1981 Mar; 24(3):238-40. PubMed ID: 6115056
[No Abstract] [Full Text] [Related]
17. DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S53-67. PubMed ID: 12211141
[No Abstract] [Full Text] [Related]
18. Current status of dopamine agonists in Parkinson's disease management.
Montastruc JL; Rascol O; Senard JM
Drugs; 1993 Sep; 46(3):384-393. PubMed ID: 7693430
[TBL] [Abstract][Full Text] [Related]
19. Serum growth hormone response to bromocriptine during a glucose tolerance test in acromegaly.
Cassar J; Mashiter K; Sullivan G; Joplin GF
Acta Endocrinol (Copenh); 1976 May; 82(1):39-46. PubMed ID: 946714
[No Abstract] [Full Text] [Related]
20. A novel ergot alkaloid as a 5-HT(1A) inhibitor produced by Dicyma sp.
Vázquez MJ; Roa AM; Reyes F; Vega A; Rivera-Sagredo A; Thomas DR; Díez E; Hueso-Rodríguez JA
J Med Chem; 2003 Nov; 46(24):5117-20. PubMed ID: 14613313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
